Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort
Pauline Tétu(Inserm), Célèste Lebbé(Inserm), M. Beylot‐Barry(Université de Bordeaux), Bastien Oriano(Hôtel-Dieu de Paris), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), S. Dalac(CHU Dijon Bourgogne), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), F. Brunet‐Possenti(Inserm), A. Ballon(Inserm), F. Aubin(Centre Hospitalier Universitaire de Besançon), Délphine Legoupil(Centre Hospitalier Régional Universitaire de Brest), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), B. Guillot(Université de Montpellier), Clara Allayous(Inserm), Raphaël Porcher(Hotel Dieu Hospital), Stéphane Dalle(Hospices Civils de Lyon), Laurent Mortier, Pierre‐Emmanuel Stoebner(Centre Hospitalier Universitaire de Nîmes), Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), Sameh Mohamed(Inserm), Brigitte Dréno(Nantes Université)
Cited by 35
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k